Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10909714 | 0.88 | ESR2 (0.52) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL10766113 | 0.88 | ESR2 (0.52) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL20083485 | 0.85 | ESR2 (0.57) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL30150 | 0.85 | ESR2 (0.57) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL16488063 | 0.85 | ESR2 (0.57) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL13621591 | 0.85 | GRIA1 (0.46) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL14649679 | 0.83 | HRH3 (0.50) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL5958188 | 0.83 | GRIA1 (0.49) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL14649680 | 0.81 | HRH3 (0.54) | HRH3KCNH2GRIA1GRIA2GRIA3 | |
| SCHEMBL11524401 | 0.81 | HRH3 (0.54) | HRH3KCNH2GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | FLI1, F12, GTF2I | HRH3 184/4885KCNH2 296/4885GRIA1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.